Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Boguniewicz, Mark [2 ]
Travers, Jeffrey [3 ]
Thyssen, Jacob [4 ]
Goldblum, Orin [5 ]
Ball, Susan [5 ]
Sun, Luna [5 ]
Chen, Sherry [6 ]
Silverberg, Jonathan [7 ]
机构：
[1] Ludwig Maximillian Univ, Munich, Germany
[2] Natl Jewish Hlth, Denver, CO USA
[3] Wright State Univ, Dayton, OH 45435 USA
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Syneos Hlth, Raleigh, NC USA
[7] Northwestern Univ, Feinberg Sch, Evanston, IL 60208 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
610
引用
收藏
页码：AB190 / AB190
页数：1
相关论文
共 50 条
  • [1] Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2)
    Reich, Kristian
    Lacour, Jean Philippe
    Costanzo, Antonio
    Brinker, Dennis R.
    Rueda, Maria Jose
    Nunes, Fabio P.
    Issa, Maher
    Paller, Amy
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB28 - AB28
  • [2] Safety of baricitinib in patients with atopic dermatitis: results of pooled data from two phase III monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2)
    Reich, K.
    Lacour, J. P.
    Costanzo, A.
    Brinker, D. R.
    Rueda, M. J.
    Nunes, F.
    Issa, M.
    Paller, A. S.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E112 - E112
  • [3] Efficacy and Safety of Baricitinib in Moderate-to-Severe Atopic Dermatitis: Results of BREEZE-AD1 and BREEZE-AD2
    Simpson, E.
    Lacour, J.
    Spelman, L.
    Ricardo, G.
    Eichenfield, L.
    Bissonnette, R.
    King, B.
    Thyssen, J.
    Silverberg, J.
    Bieber, T.
    Kenji, K.
    Tsunemi, Y.
    Costanzo, A.
    Guttman-Yassky, E.
    Delozier, A.
    Gamalo, M.
    Cardillo, T.
    Nunes, F.
    Paller, A.
    Wollenberg, A.
    Reich, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 22 - 22
  • [4] The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis
    Eichenfield, Lawrence F.
    Silverberg, Jonathan I.
    Carrascosa, Jose-Manuel
    Rubel, Diana
    Watts, Steven
    Casillas, Marta
    DeLozier, Amy M.
    Pierce, Evangeline
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB140 - AB140
  • [5] Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
    Volc, Sebastian
    Sher, Ellen R.
    Boguniewicz, Mark
    Golant, Alexandra K.
    de Bruin-Weller, Marjolein S.
    Carrascosa, Jose-Manuel
    Zhong, Jinglin
    Dawson, Zach
    Atwater, Amber Reck
    Siu, Kimberly
    Thyssen, Jacob P.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 79 - 80
  • [6] Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
    Sher, Ellen
    Boguniewicz, Mark
    Golant, Alexandra
    Zhong, Jinglin
    Atwater, Amber Reck
    Dawson, Zach
    Siu, Kimberly
    De Bruin-Weller, Marjolein
    Carrascosa, Jose-Manuel
    Thyssen, Jacob
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB148 - AB148
  • [7] Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2
    Lio, Peter
    Nosbaum, Audrey
    Cardillo, Tracy
    DeLozier, Amy
    Gamalo, Margaret
    Ball, Susan G.
    Bieber, Thomas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB28 - AB28
  • [8] Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5)
    Simpson, E.
    Forman, S.
    Silverberg, J.
    Zirwas, M.
    Maverakis, E.
    Han, G.
    Guttman-Yassky, E.
    Marnell, D.
    Bissonnette, R.
    Waibel, J.
    Nunes, F.
    DeLozier, A.
    Angle, R.
    Holzwarth, K.
    Goldblum, O.
    Zhong, J.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E97
  • [9] Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
    Simpson, Eric L.
    Forman, Seth
    Silverberg, Jonathan, I
    Zirwas, Matthew
    Maverakis, Emanual
    Han, George
    Guttman-Yassky, Emma
    Marnell, Daniel
    Bissonnette, Robert
    Waibel, Jill
    Nunes, Fabio P.
    DeLozier, Amy M.
    Angle, Robinette
    Gamalo, Margaret
    Holzwarth, Katrin
    Goldblum, Orin
    Zhong, Jinglin
    Janes, Jonathan
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) : 62 - 70
  • [10] Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
    Jacob P. Thyssen
    Timo Buhl
    Pablo Fernández-Peñas
    Kenji Kabashima
    Sherry Chen
    Na Lu
    Amy M. DeLozier
    Marta Casillas
    Sonja Ständer
    Dermatology and Therapy, 2021, 11 : 1599 - 1611
12345